Interpace Biosciences (IDXG) Stock
Company Profile
Price: $2.00
Market Cap: $8.83M
Exchange: PNK
CEO: Dr. Thomas W. Burnell Ph.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: -0.00B
Headquarters: Parsippany, NJ
Website: Interpace Biosciences
Business Summary
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Interpace Biosciences Chart
Interpace Biosciences News
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
PARSIPPANY, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2024 and provided a business and financial update.
-
globenewswire.com
2024-08-01
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined extension granted by Centers for Medicare & Medicaid Services (CMS) to Novitas, its Medicare Administrative Contractor (MAC).
-
globenewswire.com
2024-07-29
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update.
-
globenewswire.com
2024-05-09
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ending December 31, 2023.
-
globenewswire.com
2024-03-07
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update.
-
globenewswire.com
2023-11-08
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update.
-
globenewswire.com
2023-08-09
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
PARSIPPANY, NJ, July 10, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary business results for the second quarter ending June 30, 2023, and provided an update on recent activities. Final Q2 financial results are expected to be released no later than August 11, 2023.
-
globenewswire.com
2023-07-10
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”). The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close, stepping down $250,000 per quarter beginning with the quarter ending June 30, 2022. The interest rate is equal to prime plus .50%, prime being the greater of the bank's stated prime rate or the sum of the daily adjusting LIBOR rate, plus 2.5% per annum. The Bank will have a first priority security interest in substantially all of Interpace's and its subsidiaries' assets and will be senior to the existing $7.5 Million bridge loans made by the Company's private equity investors.
-
globenewswire.com
2021-10-15
Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates
Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
-
zacks.com
2021-08-10
Interpace Biosciences Earnings
This section highlight's Interpace Biosciences's earnings, including earnings call transcripts, earnings surprises, and key dates.
Interpace Biosciences Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Interpace Biosciences Earnings Dates
When is the next earnings date for IDXG?
Date: 2024-11-06Status: Unconfirmed
Time of Day: --
Estimated EPS: $-
When was the last earnings date for IDXG?
Date: 2024-08-02Fiscal Date Ending: 2024-06-30
EPS: $0.48
Estimated EPS: $-
Revenue: $12.04M
Estimated Revenue: $-
Upcoming IDXG Earnings
| Date | Estimated EPS | Time of Day | Status |
|---|---|---|---|
| 2024-11-06 | N/A | -- | Unconfirmed |
| 2025-05-07 | N/A | -- | Unconfirmed |
| 2025-07-30 | N/A | -- | Unconfirmed |
Financial Statements
This section provides financial statements for Interpace Biosciencesincluding income statements, balance sheets, and cash flow statements, both annually and quarterly.
Annual Income Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Revenue | $24.08M | $32.40M | $41.31M | $31.84M | $40.21M |
| Cost of Revenue | $15.89M | $21.67M | $23.37M | $13.61M | $17.17M |
| Gross Profit | $8.19M | $10.72M | $17.95M | $18.23M | $23.04M |
| Gross Profit Ratio | 34.02% | 33.10% | 43.44% | 57.26% | 57.30% |
| Research and Development Expenses | $2.81M | $2.79M | $1.88M | $703.00K | $636.00K |
| General and Administrative Expenses | $14.55M | $20.77M | $13.67M | $10.97M | $9.36M |
| Selling and Marketing Expenses | $11.12M | $9.25M | $10.07M | $9.12M | $10.23M |
| Selling General and Administrative Expenses | $25.66M | $30.02M | $23.74M | $20.10M | $19.60M |
| Other Expenses | $3.65M | $4.46M | $4.06M | $1.27M | $-667.00K |
| Operating Expenses | $32.12M | $37.28M | $29.68M | $22.07M | $20.23M |
| Cost and Expenses | $48.01M | $58.95M | $53.05M | $35.68M | $37.40M |
| Interest Income | $440.00K | $549.00K | $1.04M | $1.01M | $- |
| Interest Expense | $440.00K | $549.00K | $920.00K | $1.01M | $1.01M |
| Depreciation and Amortization | $4.52M | $5.50M | $5.37M | $2.56M | $1.03M |
| EBITDA | $-20.09M | $-21.63M | $-8.18M | $-3.78M | $3.84M |
| EBITDA Ratio | -83.41% | -66.75% | -19.80% | -11.88% | 9.54% |
| Operating Income | $-23.93M | $-26.55M | $-11.74M | $-3.84M | $2.81M |
| Operating Income Ratio | -99.39% | -81.96% | -28.41% | -12.06% | 6.99% |
| Total Other Income Expenses Net | $-2.73M | $407.00K | $-3.68M | $-2.00M | $-1.68M |
| Income Before Tax | $-26.67M | $-26.15M | $-15.41M | $-5.84M | $1.13M |
| Income Before Tax Ratio | -110.75% | -80.71% | -37.31% | -18.33% | 2.81% |
| Income Tax Expense | $-28.00K | $53.00K | $-667.00K | $29.00K | $17.00K |
| Net Income | $-26.64M | $-26.20M | $-14.75M | $-5.87M | $802.00K |
| Net Income Ratio | -110.63% | -80.87% | -35.69% | -18.42% | 1.99% |
| EPS | $-7.11 | $-6.50 | $-3.57 | $-1.38 | $0.19 |
| EPS Diluted | $-7.11 | $-6.50 | $-3.57 | $-1.38 | $0.18 |
| Weighted Average Shares Outstanding | 3.75M | 4.03M | 4.13M | 4.24M | 4.32M |
| Weighted Average Shares Outstanding Diluted | 3.75M | 4.03M | 4.13M | 4.24M | 4.36M |
| SEC Filing | Source | Source | Source | Source | Source |
Quarterly Income Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.72M | $4.07M | $9.20M | $5.45M | $8.25M | $9.65M | $9.83M | $11.15M | $9.47M | $10.85M | $10.38M | $9.35M | $8.19M | $8.33M | $9.83M | $11.03M | $9.08M | $10.28M | $10.27M | $12.04M |
| Cost of Revenue | $4.83M | $5.40M | $6.11M | $3.85M | $5.19M | $6.52M | $5.32M | $5.80M | $5.85M | $6.40M | $5.38M | $5.85M | $3.46M | $3.32M | $3.85M | $4.19M | $4.32M | $4.17M | $4.20M | $4.61M |
| Gross Profit | $2.89M | $-1.33M | $3.09M | $1.60M | $3.05M | $3.13M | $4.52M | $5.36M | $3.62M | $4.45M | $4.99M | $3.50M | $4.73M | $5.01M | $5.98M | $6.83M | $4.75M | $6.11M | $6.07M | $7.43M |
| Gross Profit Ratio | 37.41% | -32.56% | 33.55% | 29.31% | 37.03% | 32.44% | 45.94% | 48.01% | 38.26% | 40.99% | 48.12% | 37.44% | 57.78% | 60.14% | 60.84% | 61.99% | 52.38% | 59.41% | 59.10% | 61.71% |
| Research and Development Expenses | $857.00K | $778.00K | $809.00K | $550.00K | $763.00K | $673.00K | $637.00K | $424.00K | $416.00K | $407.00K | $299.00K | $267.00K | $191.00K | $77.00K | $149.00K | $186.00K | $149.00K | $152.00K | $137.00K | $146.00K |
| General and Administrative Expenses | $4.49M | $4.75M | $4.89M | $4.11M | $4.48M | $7.29M | $2.98M | $3.33M | $3.28M | $4.03M | $3.69M | $3.91M | $2.77M | $2.34M | $2.49M | $2.89M | $2.12M | $1.85M | $2.24M | $2.14M |
| Selling and Marketing Expenses | $2.76M | $2.99M | $2.48M | $1.60M | $2.70M | $2.48M | $2.35M | $2.78M | $2.46M | $2.48M | $2.42M | $2.77M | $2.24M | $2.14M | $2.34M | $2.60M | $2.50M | $2.79M | $2.82M | $2.89M |
| Selling General and Administrative Expenses | $7.25M | $7.74M | $7.37M | $5.70M | $7.18M | $9.77M | $5.33M | $6.10M | $5.73M | $6.51M | $6.11M | $6.68M | $5.00M | $4.47M | $4.84M | $5.50M | $4.62M | $4.64M | $5.06M | $5.03M |
| Other Expenses | $-135.00K | $209.00K | $47.00K | $438.00K | $-12.00K | $-6.00K | $-188.00K | $-96.00K | $45.00K | $-489.00K | $536.00K | $535.00K | $318.00K | $318.00K | $318.00K | $-174.00K | $-252.00K | $-259.00K | $-82.00K | $71.00K |
| Operating Expenses | $9.10M | $9.55M | $9.21M | $7.28M | $9.06M | $11.55M | $7.08M | $7.64M | $7.26M | $7.65M | $6.94M | $7.48M | $5.51M | $4.87M | $5.30M | $6.00M | $4.77M | $4.79M | $5.20M | $5.17M |
| Cost and Expenses | $13.94M | $14.95M | $15.32M | $11.13M | $14.25M | $18.07M | $12.39M | $13.44M | $13.11M | $14.05M | $12.32M | $13.33M | $8.97M | $8.19M | $9.15M | $10.19M | $9.09M | $8.96M | $9.40M | $9.79M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $36.00K | $268.00K | $-36.00K | $260.00K | $259.00K | $256.00K | $-775.00K | $- | $- |
| Interest Expense | $111.00K | $109.00K | $109.00K | $167.00K | $138.00K | $135.00K | $135.00K | $135.00K | $257.00K | $173.00K | $301.00K | $210.00K | $268.00K | $265.00K | $260.00K | $259.00K | $256.00K | $234.00K | $216.00K | $188.00K |
| Depreciation and Amortization | $1.25M | $1.28M | $1.32M | $1.39M | $1.39M | $1.40M | $1.53M | $1.41M | $1.41M | $1.02M | $781.00K | $790.00K | $635.00K | $354.00K | $356.00K | $358.00K | $240.00K | $45.00K | $160.00K | $188.00K |
| EBITDA | $-5.18M | $-9.64M | $-4.84M | $-3.94M | $-4.46M | $-7.32M | $-1.22M | $-968.00K | $-2.19M | $-2.96M | $-1.01M | $-3.12M | $-362.00K | $-731.00K | $1.05M | $1.02M | $224.00K | $1.36M | $1.03M | $2.44M |
| EBITDA Ratio | -67.11% | -236.63% | -52.60% | -72.44% | -54.01% | -75.84% | -12.39% | -8.68% | -23.08% | -27.26% | -9.71% | -33.38% | -4.42% | -8.77% | 10.69% | 9.21% | 2.47% | 13.26% | 10.07% | 20.30% |
| Operating Income | $-7.05M | $-10.83M | $-6.12M | $-5.69M | $-6.00M | $-7.94M | $-3.81M | $-2.91M | $-4.00M | $-3.28M | $-1.95M | $-3.98M | $-780.00K | $142.00K | $675.00K | $832.00K | $-16.00K | $1.32M | $874.00K | $2.26M |
| Operating Income Ratio | -91.25% | -266.00% | -66.53% | -104.44% | -72.81% | -82.27% | -38.80% | -26.05% | -42.24% | -30.19% | -18.77% | -42.58% | -9.52% | 1.70% | 6.87% | 7.55% | -0.18% | 12.83% | 8.51% | 18.74% |
| Total Other Income Expenses Net | $-973.00K | $253.00K | $47.00K | $438.00K | $-12.00K | $483.00K | $-1.44M | $-954.00K | $-318.00K | $-319.00K | $-227.00K | $111.00K | $-485.00K | $-1.54M | $-241.00K | $-174.00K | $-508.00K | $-500.00K | $-298.00K | $-117.00K |
| Income Before Tax | $-7.29M | $-10.73M | $-6.18M | $-5.42M | $-6.16M | $-8.08M | $-4.14M | $-3.37M | $-4.21M | $-3.69M | $-2.17M | $-3.87M | $-1.26M | $-1.40M | $434.00K | $399.00K | $-524.00K | $819.00K | $576.00K | $2.14M |
| Income Before Tax Ratio | -94.43% | -263.54% | -67.21% | -99.47% | -74.62% | -83.73% | -42.08% | -30.23% | -44.48% | -34.00% | -20.96% | -41.40% | -15.45% | -16.83% | 4.42% | 3.62% | -5.77% | 7.96% | 5.61% | 17.77% |
| Income Tax Expense | $9.00K | $-47.00K | $15.00K | $13.00K | $14.00K | $10.00K | $15.00K | $16.00K | $-714.00K | $17.00K | $18.00K | $16.00K | $-11.00K | $5.00K | $4.00K | $4.00K | $4.00K | $6.00K | $4.00K | $4.00K |
| Net Income | $-7.36M | $-10.72M | $-6.26M | $-5.50M | $-6.23M | $-8.14M | $-4.21M | $-3.45M | $-3.56M | $-3.73M | $-2.19M | $-3.89M | $-1.25M | $-1.41M | $351.00K | $175.00K | $-614.00K | $890.00K | $468.00K | $2.06M |
| Net Income Ratio | -95.30% | -263.32% | -68.08% | -100.92% | -75.58% | -84.42% | -42.78% | -30.89% | -37.60% | -34.36% | -21.13% | -41.57% | -15.31% | -16.89% | 3.57% | 1.59% | -6.76% | 8.66% | 4.56% | 17.12% |
| EPS | $-1.93 | $-2.80 | $-1.57 | $-1.37 | $-1.55 | $-2.02 | $-1.03 | $-0.84 | $-0.86 | $-0.89 | $-0.52 | $-0.92 | $-0.30 | $-0.33 | $0.08 | $0.04 | $-0.14 | $0.21 | $0.11 | $0.47 |
| EPS Diluted | $-1.93 | $-2.80 | $-1.56 | $-1.36 | $-1.54 | $-2.01 | $-1.03 | $-0.84 | $-0.85 | $-0.89 | $-0.52 | $-0.92 | $-0.30 | $-0.33 | $0.08 | $0.04 | $-0.14 | $0.20 | $0.11 | $0.47 |
| Weighted Average Shares Outstanding | 3.82M | 3.83M | 3.99M | 4.02M | 4.03M | 4.03M | 4.07M | 4.10M | 4.12M | 4.18M | 4.20M | 4.22M | 4.18M | 4.27M | 4.31M | 4.31M | 4.32M | 4.33M | 4.37M | 4.38M |
| Weighted Average Shares Outstanding Diluted | 3.82M | 3.83M | 4.00M | 4.03M | 4.04M | 4.04M | 4.09M | 4.10M | 4.17M | 4.18M | 4.21M | 4.23M | 4.24M | 4.27M | 4.31M | 4.32M | 4.32M | 4.34M | 4.38M | 4.40M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.32M | $2.77M | $3.31M | $4.83M | $3.50M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $2.32M | $2.77M | $3.31M | $4.83M | $3.50M |
| Net Receivables | $10.20M | $8.03M | $6.16M | $5.03M | $4.98M |
| Inventory | $1.82M | $2.05M | $1.79M | $1.22M | $1.23M |
| Other Current Assets | $167.00K | $45.00K | $108.00K | $180.00K | $614.00K |
| Total Current Assets | $16.37M | $14.12M | $12.17M | $12.15M | $10.32M |
| Property Plant Equipment Net | $10.71M | $11.73M | $10.38M | $2.92M | $2.65M |
| Goodwill | $8.43M | $8.43M | $8.43M | $- | $- |
| Intangible Assets | $33.50M | $11.35M | $7.29M | $861.00K | $- |
| Goodwill and Intangible Assets | $41.93M | $19.78M | $15.72M | $861.00K | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $42.00K | $42.00K | $160.00K | $45.00K | $45.00K |
| Total Non-Current Assets | $52.68M | $31.56M | $26.26M | $3.83M | $2.70M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $69.05M | $45.68M | $38.43M | $15.98M | $13.02M |
| Account Payables | $4.81M | $4.51M | $2.69M | $1.05M | $1.54M |
| Short Term Debt | $1.50M | $1.20M | $1.12M | $3.08M | $5.48M |
| Tax Payables | $403.00K | $334.00K | $245.00K | $262.00K | $261.00K |
| Deferred Revenue | $457.00K | $54.00K | $40.00K | $- | $261.00K |
| Other Current Liabilities | $10.52M | $12.46M | $11.83M | $10.15M | $10.19M |
| Total Current Liabilities | $17.30M | $18.23M | $15.68M | $14.28M | $17.47M |
| Long Term Debt | $5.59M | $3.54M | $12.60M | $13.01M | $4.24M |
| Deferred Revenue Non-Current | $269.00K | $136.00K | $13.00K | $- | $- |
| Deferred Tax Liabilities Non-Current | $4.08M | $4.34M | $46.54M | $- | $- |
| Other Non-Current Liabilities | $28.79M | $48.51M | $6.02M | $51.76M | $6.44M |
| Total Non-Current Liabilities | $38.73M | $56.53M | $65.16M | $64.77M | $10.68M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $56.02M | $74.76M | $80.84M | $79.05M | $28.16M |
| Preferred Stock | $26.17M | $45.68M | $46.54M | $46.54M | $46.54M |
| Common Stock | $393.00K | $402.00K | $403.00K | $405.00K | $405.00K |
| Retained Earnings | $-168.16M | $-212.12M | $-227.06M | $-249.02M | $-248.22M |
| Accumulated Other Comprehensive Income Loss | $-26.17M | $-45.68M | $-0.00B | $-0.00B | $-46.54M |
| Other Total Stockholders Equity | $180.79M | $182.63M | $137.70M | $139.00M | $232.67M |
| Total Stockholders Equity | $13.03M | $-29.08M | $-42.42M | $-63.07M | $-15.14M |
| Total Equity | $13.03M | $-29.08M | $-42.42M | $-63.07M | $-15.14M |
| Total Liabilities and Stockholders Equity | $69.05M | $45.68M | $38.43M | $15.98M | $13.02M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $69.05M | $45.68M | $38.43M | $15.98M | $13.02M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $7.10M | $4.74M | $13.72M | $16.09M | $11.19M |
| Net Debt | $4.78M | $1.97M | $10.40M | $11.26M | $7.69M |
Quarterly Balance Sheet
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.36M | $2.32M | $13.37M | $15.11M | $5.31M | $2.77M | $2.84M | $3.79M | $3.18M | $3.31M | $2.85M | $1.86M | $6.31M | $4.83M | $5.60M | $5.08M | $5.03M | $3.50M | $2.81M | $2.02M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $2.36M | $2.32M | $13.37M | $15.11M | $5.31M | $2.77M | $2.84M | $3.79M | $3.18M | $3.31M | $2.85M | $1.86M | $6.31M | $4.83M | $5.60M | $5.08M | $5.03M | $3.50M | $2.81M | $2.02M |
| Net Receivables | $14.70M | $10.20M | $11.10M | $7.76M | $8.99M | $8.03M | $7.85M | $7.33M | $6.52M | $6.16M | $7.24M | $6.45M | $4.79M | $5.03M | $4.71M | $5.53M | $4.83M | $4.98M | $5.01M | $6.21M |
| Inventory | $2.65M | $1.82M | $1.89M | $2.33M | $2.42M | $2.05M | $2.23M | $2.26M | $2.27M | $1.79M | $2.06M | $2.01M | $1.25M | $1.22M | $1.17M | $1.18M | $1.09M | $1.23M | $1.15M | $1.23M |
| Other Current Assets | $875.00K | $167.00K | $80.00K | $167.00K | $424.00K | $45.00K | $188.00K | $226.00K | $130.00K | $108.00K | $108.00K | $108.00K | $138.00K | $180.00K | $172.00K | $48.00K | $43.00K | $614.00K | $444.00K | $710.00K |
| Total Current Assets | $20.58M | $16.37M | $28.14M | $26.10M | $17.63M | $14.12M | $14.27M | $14.64M | $13.08M | $12.17M | $13.12M | $11.26M | $12.74M | $12.15M | $12.48M | $12.97M | $11.44M | $10.32M | $9.42M | $10.17M |
| Property Plant Equipment Net | $11.24M | $10.71M | $9.42M | $12.42M | $12.09M | $11.73M | $10.88M | $10.70M | $10.47M | $10.38M | $9.90M | $9.45M | $1.29M | $2.92M | $2.80M | $2.70M | $2.74M | $2.65M | $2.68M | $2.76M |
| Goodwill | $8.27M | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $34.53M | $33.50M | $32.47M | $31.44M | $12.50M | $11.35M | $10.24M | $9.13M | $8.01M | $7.29M | $6.75M | $6.21M | $1.18M | $861.00K | $544.00K | $226.00K | $27.00K | $- | $- | $- |
| Goodwill and Intangible Assets | $42.80M | $41.93M | $40.90M | $39.87M | $20.94M | $19.78M | $18.67M | $17.56M | $16.45M | $15.72M | $15.18M | $14.65M | $1.18M | $861.00K | $544.00K | $226.00K | $27.00K | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $42.00K | $42.00K | $42.00K | $42.00K | $42.00K | $42.00K | $42.00K | $290.00K | $304.00K | $160.00K | $151.00K | $129.00K | $80.00K | $45.00K | $45.00K | $45.00K | $45.00K | $45.00K | $45.00K | $45.00K |
| Total Non-Current Assets | $54.09M | $52.68M | $50.37M | $52.34M | $33.07M | $31.56M | $29.59M | $28.55M | $27.22M | $26.26M | $25.24M | $24.23M | $2.55M | $3.83M | $3.39M | $2.97M | $2.81M | $2.70M | $2.73M | $2.81M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0.00B | $-0.00B |
| Total Assets | $74.67M | $69.05M | $78.51M | $78.43M | $50.70M | $45.68M | $43.86M | $43.19M | $40.31M | $38.43M | $38.36M | $35.49M | $15.29M | $15.98M | $15.88M | $15.94M | $14.25M | $13.02M | $12.14M | $12.97M |
| Account Payables | $5.02M | $4.81M | $4.46M | $3.35M | $3.39M | $4.51M | $3.01M | $2.48M | $2.43M | $2.69M | $3.95M | $3.52M | $1.45M | $1.05M | $1.58M | $1.69M | $1.35M | $1.54M | $1.36M | $1.76M |
| Short Term Debt | $1.37M | $1.50M | $1.41M | $1.32M | $1.24M | $1.20M | $6.14M | $8.73M | $9.00M | $1.12M | $1.07M | $3.03M | $3.17M | $3.08M | $2.74M | $1.94M | $414.00K | $5.48M | $7.87M | $7.10M |
| Tax Payables | $287.00K | $403.00K | $327.00K | $311.00K | $301.00K | $334.00K | $331.00K | $289.00K | $248.00K | $245.00K | $269.00K | $218.00K | $85.00K | $262.00K | $279.00K | $222.00K | $238.00K | $261.00K | $276.00K | $308.00K |
| Deferred Revenue | $480.00K | $457.00K | $354.00K | $209.00K | $69.00K | $54.00K | $52.00K | $43.00K | $40.00K | $40.00K | $31.00K | $18.00K | $- | $- | $- | $9.07M | $9.70M | $261.00K | $276.00K | $308.00K |
| Other Current Liabilities | $10.43M | $10.52M | $9.51M | $11.22M | $10.90M | $12.46M | $11.27M | $11.56M | $11.37M | $11.83M | $11.82M | $11.88M | $10.20M | $10.15M | $9.53M | $858.00K | $858.00K | $10.19M | $9.46M | $9.86M |
| Total Current Liabilities | $17.30M | $17.30M | $15.73M | $16.10M | $15.60M | $18.23M | $20.46M | $22.81M | $22.84M | $15.68M | $16.87M | $18.45M | $14.81M | $14.28M | $13.85M | $13.56M | $12.32M | $17.47M | $18.97M | $19.03M |
| Long Term Debt | $6.54M | $5.59M | $2.58M | $7.34M | $3.75M | $3.54M | $3.33M | $3.11M | $3.23M | $12.60M | $13.26M | $12.97M | $10.17M | $13.01M | $12.88M | $12.95M | $13.12M | $4.24M | $1.34M | $1.29M |
| Deferred Revenue Non-Current | $294.00K | $269.00K | $258.00K | $239.00K | $140.00K | $136.00K | $123.00K | $25.00K | $18.00K | $13.00K | $13.00K | $13.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $4.01M | $4.08M | $4.15M | $4.21M | $4.29M | $4.34M | $4.40M | $4.45M | $46.69M | $46.54M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $22.93M | $28.79M | $2.42M | $48.85M | $2.18M | $48.51M | $1.91M | $48.57M | $6.18M | $6.02M | $52.55M | $52.01M | $51.90M | $51.76M | $51.68M | $51.63M | $51.48M | $6.44M | $6.43M | $5.15M |
| Total Non-Current Liabilities | $33.78M | $38.73M | $9.41M | $60.64M | $10.36M | $56.53M | $9.76M | $56.16M | $56.12M | $65.16M | $65.83M | $64.99M | $62.08M | $64.77M | $64.56M | $64.58M | $64.61M | $10.68M | $7.77M | $6.43M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0.00B |
| Total Liabilities | $51.08M | $56.02M | $25.14M | $76.74M | $25.96M | $74.76M | $30.22M | $78.98M | $78.95M | $80.84M | $82.70M | $83.44M | $76.89M | $79.05M | $78.42M | $78.15M | $76.93M | $28.16M | $26.75M | $25.46M |
| Preferred Stock | $13.16M | $26.17M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M | $46.54M |
| Common Stock | $383.00K | $393.00K | $402.00K | $402.00K | $402.00K | $402.00K | $402.00K | $402.00K | $403.00K | $403.00K | $404.00K | $404.00K | $404.00K | $405.00K | $405.00K | $405.00K | $405.00K | $405.00K | $406.00K | $406.00K |
| Retained Earnings | $-157.44M | $-168.16M | $-174.42M | $-179.92M | $-203.97M | $-212.12M | $-216.32M | $-219.77M | $-223.33M | $-227.06M | $-229.31M | $-233.25M | $-247.45M | $-249.02M | $-248.67M | $-248.49M | $-249.10M | $-248.22M | $-247.75M | $-245.69M |
| Accumulated Other Comprehensive Income Loss | $-13.16M | $-1.90M | $--0.00B | $-46.54M | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-46.54M | $--0.00B | $-46.54M | $-46.54M | $-405.00K | $-0.00B | $-93.11M |
| Other Total Stockholders Equity | $180.65M | $156.52M | $180.86M | $181.21M | $181.77M | $136.09M | $183.03M | $137.04M | $137.74M | $137.70M | $138.03M | $138.35M | $138.92M | $185.54M | $139.19M | $185.88M | $186.02M | $186.54M | $186.20M | $279.37M |
| Total Stockholders Equity | $23.60M | $13.03M | $53.37M | $1.69M | $24.74M | $-29.08M | $13.64M | $-35.79M | $-38.65M | $-42.42M | $-44.34M | $-47.95M | $-61.59M | $-63.07M | $-62.54M | $-62.21M | $-62.68M | $-15.14M | $-14.61M | $-12.49M |
| Total Equity | $23.60M | $13.03M | $53.37M | $1.69M | $24.74M | $-29.08M | $13.64M | $-35.79M | $-38.65M | $-42.42M | $-44.34M | $-47.95M | $-61.59M | $-63.07M | $-62.54M | $-62.21M | $-62.68M | $-15.14M | $-14.61M | $-12.49M |
| Total Liabilities and Stockholders Equity | $74.67M | $69.05M | $78.51M | $78.43M | $50.70M | $45.68M | $43.86M | $43.19M | $40.31M | $38.43M | $38.36M | $35.49M | $15.29M | $15.98M | $15.88M | $15.94M | $14.25M | $13.02M | $12.14M | $12.97M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $74.67M | $69.05M | $78.51M | $78.43M | $50.70M | $45.68M | $43.86M | $43.19M | $40.31M | $38.43M | $38.36M | $35.49M | $15.29M | $15.98M | $15.88M | $15.94M | $14.25M | $13.02M | $12.14M | $12.97M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $7.91M | $7.10M | $4.00M | $8.66M | $4.99M | $4.74M | $9.46M | $11.84M | $12.23M | $13.72M | $14.33M | $16.00M | $13.34M | $16.09M | $15.62M | $14.90M | $13.54M | $11.19M | $10.57M | $8.39M |
| Net Debt | $5.55M | $4.78M | $-9.38M | $-6.45M | $-318.00K | $1.97M | $6.62M | $8.05M | $9.05M | $10.40M | $11.48M | $14.14M | $7.03M | $11.26M | $10.03M | $9.82M | $8.50M | $7.69M | $7.76M | $6.37M |
Annual Cash Flow Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Net Income | $-26.73M | $-26.45M | $-14.94M | $-21.96M | $1.11M |
| Depreciation and Amortization | $4.19M | $5.50M | $5.37M | $2.56M | $1.03M |
| Deferred Income Tax | $18.00K | $37.00K | $38.00K | $-93.00K | $-3.22M |
| Stock Based Compensation | $1.53M | $2.24M | $1.37M | $1.30M | $630.00K |
| Change in Working Capital | $-2.08M | $5.23M | $-1.13M | $-3.05M | $-83.00K |
| Accounts Receivables | $-961.00K | $1.73M | $2.15M | $-133.00K | $49.00K |
| Inventory | $-730.00K | $- | $- | $- | $- |
| Accounts Payables | $-835.00K | $-198.00K | $-1.82M | $-735.00K | $489.00K |
| Other Working Capital | $443.00K | $3.70M | $-1.46M | $-2.18M | $-621.00K |
| Other Non Cash Items | $4.11M | $-1.08M | $575.00K | $13.54M | $4.32M |
| Net Cash Provided by Operating Activities | $-18.96M | $-14.58M | $-8.72M | $-7.69M | $3.79M |
| Investments in Property Plant and Equipment | $-131.00K | $-1.57M | $-354.00K | $-322.00K | $-470.00K |
| Acquisitions Net | $-13.83M | $- | $39.00K | $6.53M | $383.00K |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $13.00K | $- | $39.00K | $6.53M | $383.00K |
| Net Cash Used for Investing Activities | $-13.95M | $-1.57M | $-315.00K | $6.21M | $-87.00K |
| Debt Repayment | $-6.02M | $-3.00M | $-7.92M | $-3.00M | $-5.00M |
| Common Stock Issued | $6.48M | $434.00K | $335.00K | $108.00K | $- |
| Common Stock Repurchased | $-41.00K | $-52.00K | $- | $-108.00K | $-32.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $28.74M | $19.22M | $16.57M | $9.00M | $-2.50M |
| Net Cash Used Provided by Financing Activities | $29.16M | $16.61M | $8.98M | $3.00M | $-5.03M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-500.00K |
| Net Change in Cash | $-3.75M | $451.00K | $-58.00K | $1.51M | $-1.83M |
| Cash at End of Period | $2.32M | $2.77M | $3.31M | $4.83M | $3.50M |
| Cash at Beginning of Period | $6.07M | $2.32M | $3.37M | $3.31M | $5.33M |
| Operating Cash Flow | $-18.96M | $-14.58M | $-8.72M | $-7.69M | $3.79M |
| Capital Expenditure | $-131.00K | $-1.57M | $-354.00K | $-322.00K | $-470.00K |
| Free Cash Flow | $-19.09M | $-16.15M | $-9.07M | $-8.01M | $3.32M |
Quarterly Cash Flow Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-7.36M | $-10.73M | $-6.26M | $-5.50M | $-6.55M | $-8.14M | $-4.21M | $-3.45M | $-3.56M | $-3.73M | $-2.25M | $-3.94M | $-14.21M | $-1.56M | $351.00K | $175.00K | $-528.00K | $813.00K | $572.00K | $2.14M |
| Depreciation and Amortization | $1.16M | $1.28M | $1.24M | $1.30M | $1.56M | $1.40M | $1.53M | $1.41M | $1.41M | $1.02M | $781.00K | $790.00K | $635.00K | $354.00K | $356.00K | $358.00K | $240.00K | $45.00K | $160.00K | $188.00K |
| Deferred Income Tax | $10.00K | $18.00K | $224.00K | $-23.00K | $-1.17M | $37.00K | $-99.00K | $168.00K | $-72.00K | $-36.00K | $- | $- | $- | $-93.00K | $- | $- | $-315.00K | $-111.00K | $- | $- |
| Stock Based Compensation | $256.00K | $289.00K | $418.00K | $400.00K | $563.00K | $806.00K | $286.00K | $551.00K | $477.00K | $54.00K | $325.00K | $334.00K | $520.00K | $125.00K | $192.00K | $157.00K | $152.00K | $129.00K | $79.00K | $53.00K |
| Change in Working Capital | $1.05M | $-558.00K | $-2.85M | $4.10M | $-267.00K | $4.24M | $-2.74M | $-568.00K | $794.00K | $1.38M | $-74.00K | $281.00K | $-2.71M | $-550.00K | $218.00K | $-499.00K | $1.03M | $-831.00K | $-808.00K | $-853.00K |
| Accounts Receivables | $2.00M | $1.02M | $148.00K | $2.56M | $-1.08M | $100.00K | $317.00K | $524.00K | $947.00K | $360.00K | $-1.08M | $795.00K | $395.00K | $-240.00K | $317.00K | $-814.00K | $699.00K | $-153.00K | $-49.00K | $-1.20M |
| Inventory | $31.00K | $-1.52M | $-2.65M | $2.63M | $729.00K | $3.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $--0.00B | $-0.00B | $- | $- |
| Accounts Payables | $-1.30M | $-69.00K | $-356.00K | $-1.11M | $145.00K | $1.12M | $-1.53M | $-498.00K | $-52.00K | $267.00K | $1.24M | $-441.00K | $-1.24M | $-288.00K | $532.00K | $78.00K | $-382.00K | $261.00K | $-176.00K | $163.00K |
| Other Working Capital | $321.00K | $8.00K | $16.00K | $17.00K | $-58.00K | $25.00K | $-1.52M | $-594.00K | $-101.00K | $753.00K | $-226.00K | $-73.00K | $-1.86M | $-22.00K | $-849.00K | $237.00K | $712.00K | $-939.00K | $-583.00K | $184.00K |
| Other Non Cash Items | $111.00K | $3.30M | $109.00K | $167.00K | $138.00K | $74.00K | $219.00K | $65.00K | $279.00K | $89.00K | $-39.00K | $-384.00K | $12.52M | $1.45M | $16.00K | $220.00K | $527.00K | $1.09M | $563.00K | $1.35M |
| Net Cash Provided by Operating Activities | $-4.77M | $-6.40M | $-7.12M | $449.00K | $-5.72M | $-1.58M | $-5.01M | $-1.82M | $-676.00K | $-1.22M | $-1.25M | $-2.92M | $-3.24M | $-276.00K | $1.13M | $411.00K | $1.10M | $1.14M | $-58.00K | $1.40M |
| Investments in Property Plant and Equipment | $-57.00K | $-26.00K | $- | $-913.00K | $-362.00K | $-300.00K | $- | $-48.00K | $-144.00K | $-162.00K | $-19.00K | $-67.00K | $-40.00K | $-196.00K | $-65.00K | $-111.00K | $-152.00K | $-142.00K | $-28.00K | $-197.00K |
| Acquisitions Net | $-13.83M | $-13.83M | $- | $- | $- | $- | $39.00K | $- | $- | $- | $- | $- | $7.43M | $-903.00K | $- | $-117.00K | $500.00K | $-117.00K | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-13.83M | $13.83M | $- | $- | $- | $- | $39.00K | $-48.00K | $- | $9.00K | $- | $- | $7.43M | $-903.00K | $- | $-117.00K | $500.00K | $117.00K | $- | $-225.00K |
| Net Cash Used for Investing Activities | $-13.89M | $-26.00K | $- | $-913.00K | $-362.00K | $-300.00K | $39.00K | $-48.00K | $-144.00K | $-162.00K | $-19.00K | $-67.00K | $7.39M | $-1.10M | $-65.00K | $-228.00K | $348.00K | $-142.00K | $-28.00K | $-197.00K |
| Debt Repayment | $- | $-750.00K | $-1.80M | $- | $- | $-1.80M | $-4.93M | $-2.57M | $- | $-9.19M | $-1.00M | $-2.00M | $- | $- | $-300.00K | $-700.00K | $-1.50M | $-2.50M | $-600.00K | $-2.00M |
| Common Stock Issued | $- | $516.00K | $434.00K | $- | $- | $- | $108.00K | $- | $227.00K | $-335.00K | $59.00K | $- | $47.00K | $2.00K | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-32.00K | $-9.00K | $- | $- | $- | $-52.00K | $- | $- | $- | $- | $- | $- | $- | $-108.00K | $- | $- | $- | $-32.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $16.84M | $5.88M | $19.54M | $2.20M | $-3.71M | $1.80M | $4.93M | $2.47M | $-18.00K | $1.60M | $1.00M | $2.00M | $47.00K | $-106.00K | $-300.00K | $-700.00K | $-1.50M | $-2.50M | $-600.00K | $-2.00M |
| Net Cash Used Provided by Financing Activities | $16.80M | $6.39M | $18.17M | $2.20M | $-3.71M | $-52.00K | $5.03M | $2.47M | $209.00K | $1.26M | $1.06M | $2.00M | $47.00K | $-106.00K | $-300.00K | $-700.00K | $-1.50M | $-2.53M | $-600.00K | $-2.00M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.03M | $- | $-1.03M | $- | $- |
| Net Change in Cash | $-1.85M | $-37.00K | $11.05M | $1.74M | $-9.80M | $-1.94M | $67.00K | $602.00K | $-611.00K | $-116.00K | $-214.00K | $-985.00K | $4.19M | $-1.48M | $768.00K | $-517.00K | $-547.00K | $-1.53M | $-686.00K | $-793.00K |
| Cash at End of Period | $2.36M | $2.32M | $13.37M | $15.11M | $5.31M | $3.37M | $3.44M | $4.04M | $3.43M | $3.31M | $3.10M | $2.12M | $6.31M | $4.83M | $5.60M | $5.08M | $5.03M | $3.50M | $2.81M | $2.02M |
| Cash at Beginning of Period | $4.21M | $2.36M | $2.32M | $13.37M | $15.11M | $5.31M | $3.37M | $3.44M | $4.04M | $3.43M | $3.31M | $3.10M | $2.12M | $6.31M | $4.83M | $5.60M | $5.58M | $5.03M | $3.50M | $2.81M |
| Operating Cash Flow | $-4.77M | $-6.40M | $-7.12M | $449.00K | $-5.72M | $-1.58M | $-5.01M | $-1.82M | $-676.00K | $-1.22M | $-1.25M | $-2.92M | $-3.24M | $-276.00K | $1.13M | $411.00K | $1.10M | $1.14M | $-58.00K | $1.40M |
| Capital Expenditure | $-57.00K | $-26.00K | $- | $-913.00K | $-362.00K | $-300.00K | $- | $-48.00K | $-144.00K | $-162.00K | $-19.00K | $-67.00K | $-40.00K | $-196.00K | $-65.00K | $-111.00K | $-152.00K | $-142.00K | $-28.00K | $-197.00K |
| Free Cash Flow | $-4.83M | $-6.43M | $-7.12M | $-464.00K | $-6.08M | $-1.88M | $-5.01M | $-1.87M | $-820.00K | $-1.38M | $-1.27M | $-2.98M | $-3.28M | $-472.00K | $1.07M | $300.00K | $953.00K | $998.00K | $-86.00K | $1.21M |
Interpace Biosciences Dividends
Understand Interpace Biosciences's dividend history, dividend yield, payout ratio, and more.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
-8.06x
Interpace Biosciences Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|
Valuation
Analyze the market cap, enterprise value, and valuation metrics for Interpace Biosciences.
Market Cap & Enterprise Value
Market Cap: $8.83M
Enterprise Value: $12.36M
Valuation Ratios
P/E Ratio: 5.81
P/B Ratio: -0.31
P/CF Ratio: 1.23
Valuation Multiples
E/V to Sales: 0.31
E/V to EBITDA: 3.22
Market Cap & Enterprise Value
Market capitalization and enterprise value provide an understanding of a company's market value and total value, respectively.
- Market Cap: The total market value of a company's outstanding shares of stock. It represents the company's equity value and is calculated by multiplying the current share price by the total number of outstanding shares.
- Enterprise Value (EV): A measure of a company's total value, often seen as a more comprehensive alternative to equity market capitalization. It includes market cap plus debt, minority interest, and preferred shares, minus total cash and cash equivalents.
Valuation Ratios
Valuation ratios are used to evaluate the value of a company compared to its earnings, book value, and cash flow.
- P/E Ratio: Price to Earnings Ratio, indicating how much investors are willing to pay for a dollar of earnings.
- P/B Ratio: Price to Book Ratio, comparing the company's market value to its book value. A lower ratio may indicate undervaluation.
- P/CF Ratio: Price to Cash Flow Ratio, evaluating the market value relative to the operating cash flow. A lower ratio can signal a more attractive investment.
Valuation Multiples
Valuation multiples help assess a company's value relative to its revenue and earnings.
- EV to Sales: Enterprise Value to Sales, comparing the enterprise value to sales revenue. A lower ratio can indicate a more attractive investment.
- EV to EBITDA: Enterprise Value to EBITDA, comparing the enterprise value to earnings before interest, taxes, depreciation, and amortization. A lower ratio suggests a company may be undervalued.
Interpace Biosciences Growth
View income_statement_chart2_annual_data financial growth metrics for Interpace Biosciences, including income statement, balance sheet, and cash flow growth.
Income Growth
Revenue Growth: 17.22%
Operating Income Growth: 158.24%
Cash Flow Growth
Net Income Growth: 273.43%
Free Cash Flow Growth: 1503.49%
Balance Sheet Growth
Total Assets Growth: 6.84%
Total Liabilities Growth: -4.80%
Income Growth
This section highlights key metrics related to income growth, showing how the company’s revenue and operating income have changed over time:
- Revenue Growth: The increase in a company's sales over time. It is a measure of how quickly the company is growing its revenue. This chart shows the historical trend of revenue growth.
- Operating Income Growth: The growth rate of a company's operating income, which is the income earned from its normal business operations. This chart helps to assess the company's operational efficiency and profitability growth over time.
Cash Flow Growth
This section highlights key metrics on the company's cash flow growth, reflecting changes in net income and free cash flow over time.
- Net Income Growth: The increase in a company's net profit over time. It reflects the company's ability to increase its profitability. This chart provides insight into how the company's bottom line has grown.
- Free Cash Flow Growth: The growth in a company's free cash flow, which is the cash generated by the company after accounting for capital expenditures. This chart is important for understanding the company's financial flexibility and ability to fund operations and growth.
Balance Sheet Growth
This section highlight key metrics related to balance sheet growth, which indicate how the company’s total assets and liabilities have changed over time:
- Total Assets Growth: The rate at which a company's total assets are increasing over time. This chart indicates how the company's asset base is expanding, which can be a sign of growth and investment in future operations.
- Total Liabilities Growth: The rate at which a company's total liabilities are increasing over time. This chart helps to assess the company's financial leverage and risk over time.
Peers: Medical - Diagnostics & Research
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Intelligent Bio Solutions Inc.
INBS
|
$6.76M | $1.59 | $-6.39 | $-0.29 | $0.35 |
bioAffinity Technologies, Inc.
BIAF
|
$24.55M | $1.82 | $-0.91 | $-1.62 | $2.65 |
SeqLL Inc.
SQL
|
$185.31M | $6.60 | $0.00 | $0.00 | $0.00 |
Biocept, Inc.
BIOC
|
$- | $0.43 | $-56.78 | $-0.28 | $1.01 |
FONAR Corporation
FONR
|
$102.52M | $16.20 | $1.66 | $9.70 | $0.62 |
Burning Rock Biotech Limited
BNR
|
$38.01M | $3.71 | $-6.38 | $-10.77 | $9.16 |
Sera Prognostics, Inc.
SERA
|
$233.61M | $7.21 | $-1.16 | $-5.15 | $2.66 |
Olink Holding AB (publ)
OLK
|
$3.24B | $26.08 | $-0.26 | $-98.51 | $6.20 |
LumiraDx Limited
LMDX
|
$- | $0.02 | $-1.59 | $-0.56 | $-2.27 |
HTG Molecular Diagnostics, Inc.
HTGM
|
$1.06M | $0.48 | $-24.28 | $-0.16 | $0.66 |
bioAffinity Technologies, Inc.
BIAFW
|
$26.98M | $2.00 | $-0.91 | $-1.62 | $2.65 |
Genetron Holdings Limited
GTH
|
$127.29M | $4.03 | $-9.53 | $-2.43 | $3.94 |
Exagen Inc.
XGN
|
$52.16M | $3.00 | $-1.34 | $-1.49 | $1.55 |
OncoCyte Corporation
OCX
|
$38.65M | $2.89 | $-3.63 | $-0.69 | $0.75 |
Personalis, Inc.
PSNL
|
$276.09M | $5.19 | $-2.25 | $-0.93 | $0.78 |
iSpecimen Inc.
ISPC
|
$3.42M | $5.23 | $-1.23 | $-8.15 | $9.29 |
Trinity Biotech plc
TRIB
|
$13.64M | $1.20 | $-3.14 | $-0.69 | $-0.69 |
More metrics for Interpace Biosciences
Access more key metrics, financials, ratios, and more with the links below.